MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple Turns 50: From Garage Startup to AI Crossroads 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
STAMFORD, Conn., Aug. 01, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the second quarter ended June 30, 2017 on August 8, 2017 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
